Infant Bacterial Therapeutics AB (publ)
The answer first
Does Infant Bacterial Therapeutics beat the market?
Yes, Infant Bacterial Therapeutics has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 22% of Nordic stocks
- Quality16
- Value1
- Trend93
No. 123 of 195 in healthcare
Max for seven days
Follow Infant Bacterial Therapeutics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Infant Bacterial Therapeutics
Your first answer is free, no account needed.
Do you own Infant Bacterial Therapeutics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Infant Bacterial Therapeutics and a few more. Free, no card.
Super Stock+46.4%In short
- Infant Bacterial Therapeutics has risen 52.4% over the past year, including dividends.
- Overall, Infant Bacterial Therapeutics ranks better than 22% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 74.6%. The price is 73.3% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 22% of Nordic stocks.
No. 123 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 174 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−281.6%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 189 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity28.7
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 21 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+6.0%
- 6 months+34.5%
- 9 months+26.8%
- 12 months+52.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Infant Bacterial Therapeutics
5 funds we follow own Infant Bacterial Therapeutics. The share is how much of the fund the stock makes up.
- Sweden5
From the funds' latest known holdings.
About Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.


See the full analysis of Infant Bacterial Therapeutics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card